Subcutaneous bortezomib

DRUG3 trials

Sponsors

Oncotherapeutics, The First Affiliated Hospital of Soochow University, Cancer Trials Ireland

Conditions

Multiple MyelomaMultiple Myeloma Proved by Laboratory Tests

Phase 1

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China

The First Affiliated Hospital of Soochow UniversityMultiple Myeloma Proved by Laboratory Tests

Start: 2014-05-31End: 2017-06-30Target: 20Updated: 2015-08-18

Phase 2

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

TerminatedNCT01695330

OncotherapeuticsMultiple Myeloma

Start: 2012-05-31End: 2015-10-31Updated: 2017-01-16

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

CompletedNCT02219178

Cancer Trials IrelandMultiple Myeloma

Start: 2014-11-30End: 2020-04-30Updated: 2020-07-17

Related Papers

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma

American Journal of Hematology2022-02-084 citations